Publications

A listing of publications, sorted by A-Z and topics, on the Australian Government Department of Health websites.

Page last updated: 26 April 2018 (this page is generated automatically and reflects updates to other content within the website)

By Title

View publications by title beginning with...

By Health Topic

View publications by health topic


Alternatively view all 606 publications or the most recently added publications on this website.

Currently displaying the 10 most recently added publications:

PublicationYearStatusHealth topics

End-of-life care brochure: Aboriginal and Torres Strait Islander

Caring for your mob at the end of their life.

2018Current

End-of-life care brochures: English and multilingual

What do you want for your end-of-life care?

2018Current

Conversation Guide: What Matters To Me

Talking about end-of-life care is different for everyone. Some people find it overwhelming and confronting, others may be more accepting.

2018Current

Explanatory Note
2015-16 Annual Reconciliation of National Health Reform funding

2018Current

Examination of Australian Government Indigenous Ear and Hearing Health Initiatives

This report provides the findings and recommendations of an examination of the progress and outcomes of Australian Government Indigenous ear and hearing health initiatives.

2018Current

Consumer Representative Forum on Hearing Communiqué 10 February 2018

The Hon Ken Wyatt AM MP, Minister for Aged Care and Minister for Indigenous Health, met with consumer representative groups on Saturday 10 February 2018 to discuss contemporary issues faced by families and individuals living with a hearing impairment, listen to their views on hearing related topics and provide an opportunity for representatives to discuss key issues that are affecting consumers.

2018Current

National position statement for the management of latent tuberculosis infection

The primary role of any tuberculosis (TB) control program is to ensure the prompt identification and effective treatment of active disease. The host immune system often succeeds in containing the initial (or primary) infection with Mycobacterium tuberculosis (Mtb), but may fail to eliminate the pathogen. The persistence of viable organisms explains the potential for the development of active disease years or even decades after infection. This is known as latent tuberculosis infection (LTBI) although, rather than a distinct entity, this probably represents part of a dynamic spectrum. Individuals with LTBI are asymptomatic and it is therefore clinically undetectable. The World Health Organization (WHO) estimates that one-third of the global population has been infected with Mtb, with highest prevalence of LTBI in countries/regions with the highest prevalence of active disease. In 2013, 88% of 1322 notifications in Australia were in the overseas-born population (incidence 19.5 per 100,000 v. 1.0 per 100,000), with this proportion rising over the course of the last decade. Combined with epidemiological evidence of low local transmission, this strongly implies that the vast majority resulted from reactivation of latent infection acquired prior to immigration. Contrasting trends in TB incidence in other developed countries probably reflect differences in policy regarding LTBI. Conclusion: The diagnosis and treatment of LTBI represents an important opportunity for intervention by jurisdictional TB control programs.

2017Current

The epidemiology of tuberculosis in the Australia Capital Territory, 2006-2015

This paper reviews surveillance data to describe the epidemiology of tuberculosis in the Australian Capital Territory over a 10 year period between 2006 and 2015.

2017Current

Australian Meningococcal Surveillance Programme, 1 April to 30 June 2017

The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and by non-culture based techniques. Data contained in quar­terly reports are restricted to a description of the number of cases of IMD by jurisdiction and serogroup, where known. A full analysis of laboratory confirmed cases of IMD in each calen­dar year is contained in the AMSP annual reports.

2017Current

Annual report: surveillance of adverse events following immunisation in Australia, 2015

This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Therapeutic Goods Administration (TGA) for 2015. It also describes reporting trends over the 16-year period 1 January 2000 to 31 December 2015.

2017Current